Ipamorelin releases a clean growth-hormone pulse — and the newest studies are what this page leads with.

The short version

Ipamorelin is a small lab-made peptide (a short chain of five amino acids) that tells the pituitary gland to release a quick burst of growth hormone. Its claim to fame, set out in its founding 1998 study, is being selective: it raises growth hormone without meaningfully raising the stress hormone cortisol or the milk hormone prolactin ^[1]. That clean profile is why researchers keep studying it and why it is often paired with a second peptide called CJC-1295.

Here is the honest state of play. Almost all of the strong evidence comes from animals and a handful of short human studies. The one real human trial that tested whether it helped a medical condition (slow bowel recovery after surgery) did not work ^[3]. It has never been approved as a medicine anywhere. The newest work, a 2024 ferret study and several 2026 reviews, treats it as promising but unproven ^[5]. What people in research-use communities report, including the downsides, is laid out plainly on the effects page.

What the newest ipamorelin studies measured

Start with the freshest data. In a 2024 ferret study, ipamorelin given into the abdomen at 1 to 3 mg/kg cut chemotherapy-driven body-weight loss by about 24% on the last day of the delayed phase (48 to 72 hours), though it did no anti-emetic (anti-nausea) work at all ^[5]. It is the most recent published in-vivo ipamorelin experiment, and it points at body-weight defense through a peripheral route rather than a brain one.

The 2026 reviews keep the same posture. A USC Keck School of Medicine narrative review reported that CJC-1295 combined with ipamorelin improved maximum tetanic tension (peak sustained muscle force) in a steroid-induced muscle-loss model in mice, while stressing that the evidence is limited to animals ^[15]. A sports-medicine review classed ipamorelin as an investigational growth-hormone-axis peptide with no reproducible human evidence for musculoskeletal outcomes and recommended confining its use to rigorous research protocols ^[18]. A broader peptide-therapy review flagged the same gap: real biological activity, but human trials still missing ^[17]. The pattern across 2024 and 2026 is consistent: active mechanism, animal-level signals, human proof still owed.

Where the selectivity finding came from

The headline number that defines ipamorelin is two decades old and still cited in every new review. In its founding 1998 characterization, ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) released growth hormone potently in rat pituitary cells, anaesthetised rats, and conscious swine, with a swine ED50 (the dose that produces half the maximum effect) of 2.3 nmol/kg versus 3.9 nmol/kg for the older peptide GHRP-6 ^[1]. The decisive part: it did not raise cortisol or ACTH above background even at doses more than 200-fold above its growth-hormone ED50 ^[1]. That made it the first highly growth-hormone-selective secretagogue, and that selectivity is the through-line of the whole Ipamorelin research record.

The one human efficacy trial, and what it returned

Ipamorelin has exactly one published Phase 2 randomized controlled trial, and it is the most important honesty anchor on this site. In NCT00672074, 114 adults undergoing bowel resection received 0.03 mg/kg intravenously twice daily for up to seven days ^[3]. The trial missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that was not statistically significant (p=0.15) ^[3]. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of placebo, so no ipamorelin-specific safety signal emerged in that short window, but efficacy was not demonstrated ^[3]. No Phase 3 trial followed. Human pharmacokinetics were characterized separately in eight volunteers per dose, showing a terminal half-life of about 2 hours ^[2].

What this site is, in one paragraph

This is an independent editorial digest of the published ipamorelin literature, organized so the newest studies lead. Every quantitative claim here, every dose, half-life, percentage, and ED50, maps to a numbered citation you can check on the Ipamorelin references page. It is not a clinic and not a store. "Medicine" in the domain name describes the subject matter, the medical-research literature, not an approved medicine and not a service offered here. For the human-interest side, the reported benefits and side effects plus who has reason to be careful, see the effects page.